Onco-Urologie Prédictive

Recent papers from Onco-Urologie Prédictive

1. Recovering anaerobic bacterial genomes in saliva, tumour and blood whole genome sequencing data from patients with prostate cancernpj Biofilms and Microbiomes · 2026
2. The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancerNature Communications · 2026
3. Role of Second-Look Ureterorenoscopy After Endoscopic Treatment of Upper Tract Urothelial CarcinomaCancers · 2026
4. Active surveillance for intermediate‐risk prostate cancer: a systematic review and pooled analysisBJU International · 2026
5. Performance of MRI-Based vs Clinical T Staging in Localized Prostate CancerJAMA Network Open · 2026
6. Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-makingEuropean Urology Oncology · 2026
7. Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisEuropean Urology Focus · 2026
8. Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder CancerJournal of the National Comprehensive Cancer Network · 2026
9. Diagnostic Accuracy of Liquid-Based Biomarkers for Detecting and Risk Stratifying Upper Tract Urothelial Cancers: A Diagnostic Test Systematic Review by the EAU Guidelines UTUC PanelEuropean Urology Oncology · 2026
10. Neoadjuvant Intravesical Therapy for Patients with Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.2026
11. Germline polygenic score for prostate cancer aggressiveness2026
12. Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic ReviewEuropean Urology Oncology · 2026
13. Risk stratification of Ta high-grade non–muscle-invasive bladder cancer: Insights from a multicenter cohort studyUrologic Oncology Seminars and Original Investigations · 2026
14. Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell CarcinomaClinical Genitourinary Cancer · 2026
15. First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysisWorld Journal of Urology · 2026
16. Predictive Value of Prior Non–muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC CohortEuropean Urology Oncology · 2025
17. Clinical and pathological features associated with chromophobe renal cell carcinoma recurrence: analysis from a nationwide cohort (UroCCR-136)European Urology Open Science · 2025
18. Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH)Progrès en Urologie · 2025
19. Updated 2025 French guidelines for renal cell carcinomaThe French Journal of Urology · 2025
20. ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)Annals of Oncology · 2025